Phase II Trial Comparing IOUS-Guided Margin Selection in Crohn's Disease Surgery
This Phase II trial could redefine surgical standards for Crohn's disease, potentially enhancing patient outcomes and influencing competitive practices. The results may position the Cleveland Clinic as a leader in innovative surgical techniques, impacting market dynamics in gastroenterology.
Phase II
Crohn's Disease surgical practices
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
This Phase II trial could redefine surgical standards for Crohn's disease, potentially enhancing patient outcomes and influencing competitive practices. The results may position the Cleveland Clinic as a leader in innovative surgical techniques, impacting market dynamics in gastroenterology.
Why it matters
This Phase II trial could redefine surgical standards for Crohn's disease, potentially enhancing patient outcomes and influencing competitive practices. The results may position the Cleveland Clinic as a leader in innovative surgical techniques, impacting market dynamics in gastroenterology.
What changed
Trial Update
Analysis
A Phase II trial is underway to compare intraoperative ultrasound (IOUS)-guided margin selection with standard methods in ileocolic resection for terminal ileal Crohn's disease.
This Phase II trial could redefine surgical standards for Crohn's disease, potentially enhancing patient outcomes and influencing competitive practices. The results may position the Cleveland Clinic as a leader in innovative surgical techniques, impacting market dynamics in gastroenterology.
Monitor trial results and any subsequent changes in clinical guidelines or practices related to Crohn's disease surgery.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.